Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
KaliVir Immunotherapeutics
Sotio Biotech Inc.
Novartis
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Incyte Corporation
Incyte Corporation
Turnstone Biologics, Corp.
Symphogen A/S
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Xencor, Inc.
Ascentage Pharma Group Inc.
AbbVie
MacroGenics
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Mannkind Corporation